Trial Profile

An expanded access program of Vamorolone for the patients with Duchenne-muscular-dystrophy in China

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 14 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vamorolone (Primary)
Indications Duchenne muscular dystrophy
Focus Expanded access; Therapeutic Use

Most Recent Events

14 Jun 2024 Status changed from planning to recruiting.
14 Jun 2024 New trial record
10 Jun 2024 According to Santhera Pharmaceuticals media release, In April 2024, the Hainan Medical Products Administration (HMPA) authorized the EAP for AGAMREE based on local policies, AGAMREEs existing overseas approvals (U.S., EU, UK) and its demonstrated ability to address urgent clinical needs in DMD.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com